In contrast to other mistletoe products, the standardised manufacture of abnobaVISCUM is performed by using a patented pressing procedure. Using this manufacturing process to produce the pressed juice ensures that the entire range of plant ingredients is transferred to the extract. The plant extract contains 75% of the plant material used. With the help of a buffer solution, the various concentrations of abnobaVISCUM are then produced.
Plant material from both a summer and a winter harvest is used. These two raw materials are processed separately to pressed juice and are subsequently mixed in another patented procedure. This mixture is produced because investigations have shown that various pharmacologically active substances are present in the plant to different extents, depending on the season. For example, particularly large quantities of polysaccharides are found in the white mistletoe berries, which are only harvested with the winter harvest.
The particular form of extracting abnobaVISCUM affects the formation of liposomes in abnobaVISCUM. Liposomes are cell-like structures in or to which one can include or attach active substances. Liposomes can thus enable targeted transport of the active substances to the “site of action”, i.e. the tumour. The medical term for this process is “drug targeting”.
The picture below shows you what liposomes look like.
Detail of an electron microscopic image of liposomes in abnobaVISCUM.
Liposomes and those contained in abnobaVISCUM are among the subjects of our current research, which characterises the liposomes and investigates thier impact on the efficacy and tolerability of the medicinal product.
Pharmaceutical research is generously recognised by public funding, for example:
Central Innovation Programme (SME) (small and medium-sized enterprises)
(Zentrales Innovationsprogramm Mittelstand (ZIM))
European Union: Marie Curie Actions
Together with the Universities of Utrecht (NL), Uppsala (S) and Karlsruhe (D).
Marie Curie Actions Uni Uetrecht and Karlsruhe
“Novel drug deliver system produced by centrifugal technologies – composed to minimize adverse immune reactions and designed for optimized therapeutic effects.”
One of the results of this research is that the “mode of action” of ABNOBA products and the destruction of cancer cells by lectins can be explained in detail. Cf. the following picture and its explanation:
How lectins bring about the programmed cell death of cancer cells, referred to as apoptosis:
The picture shows the uptake of the cell nucleus (blue) inside the cancer cell already penetrated by the mistletoe lectins (red) that are now penetrating the nucleus via the Golgi apparatus (green) to induce the programmed cell death. Only ABNOBA mistletoe preparations provide this scientific evidence of the active principle (1 micrometre [µm] is equivalent to 1/1,000th of a millimetre).
You can also watch how the cells are ”destroyed“ in a film composed of images made by confocal microscopy. Click on the following link: